YET2 Antibody

What is YEATS2 and what is its role in cellular processes?

YEATS2 (YEATS domain containing 2) is a scaffolding subunit of the ATAC complex that functions as a selective histone crotonylation reader and is involved in histone acetylation processes. Research indicates that YEATS2 plays significant roles in chromatin regulation and has been associated with the progression of various tumors . Understanding YEATS2 function is critical for researchers investigating epigenetic modifications and their impact on gene expression.

When conducting experiments involving YEATS2, researchers should consider its molecular weight (calculated at 151 kDa) and its interactions with chromatin components. Experimental designs should account for YEATS2's role in both normal cellular processes and pathological conditions where its dysregulation may contribute to disease progression.

What applications can YEATS2 antibodies be used for in research settings?

YEATS2 antibodies have been validated for multiple experimental applications including Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC), and ELISA . The versatility of these applications allows researchers to examine YEATS2 expression, localization, and interactions across various experimental contexts.

The methodological approach for using YEATS2 antibodies varies by application:

For IHC applications, antigen retrieval with TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 may also be used as an alternative .

How should YEATS2 antibodies be stored and handled to maintain optimal reactivity?

For optimal performance, YEATS2 antibodies should be stored at -20°C in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Under these conditions, the antibody remains stable for one year after shipment. Small volume preparations (20 μl) contain 0.1% BSA to enhance stability.

To maintain antibody integrity, researchers should follow these methodological guidelines:

• Aliquot antibodies upon receipt to minimize freeze-thaw cycles

• Thaw aliquots completely before use and mix gently

• Centrifuge briefly to collect contents at the bottom of the tube

• Keep antibodies on ice during experiment preparation

• Return to -20°C immediately after use

How can I optimize YEATS2 antibody performance for detecting low-abundance targets?

When dealing with low-abundance YEATS2 expression, several methodological approaches can enhance detection sensitivity:

For Western blotting with low YEATS2 abundance:

• Increase protein loading (up to 50-80 μg per lane)

• Use higher antibody concentration (1:200 dilution)

• Extend primary antibody incubation time (overnight at 4°C)

• Implement signal amplification using HRP-conjugated polymers

• Use enhanced chemiluminescence substrate with extended exposure times

For immunoprecipitation of low-abundance YEATS2:

• Increase starting material (3.0 mg of total protein)

• Use maximum recommended antibody amount (4.0 μg)

• Extend binding reaction time (overnight at 4°C with gentle rotation)

• Optimize washing conditions to reduce background while preserving specific binding

It's crucial to include appropriate positive controls (such as Jurkat cell lysate) that have confirmed YEATS2 expression to validate assay performance .

What are the key considerations when comparing YEATS2 expression between normal and diseased tissues?

When designing experiments to compare YEATS2 expression between normal and pathological samples, researchers should implement:

• Standardized sample preparation: Use identical fixation times, processing protocols, and antigen retrieval methods for all samples to ensure comparable epitope accessibility.

• Quantitative assessment methods: Employ digital image analysis for IHC to quantify staining intensity and distribution patterns rather than relying solely on qualitative evaluation.

• Multiple detection methods: Validate findings using at least two independent techniques (e.g., IHC and Western blot) to confirm expression differences.

• Appropriate controls: Include tissue-matched normal controls for each pathological sample to account for tissue-specific YEATS2 expression variations.

• Statistical analysis plan: Determine appropriate sample sizes through power analysis and apply suitable statistical tests for comparing expression levels.

Research has demonstrated YEATS2 alterations in certain cancer types, making careful comparative analysis essential for understanding its potential role in disease progression .

How can I assess YEATS2 antibody cross-reactivity and specificity in experimental systems?

Ensuring antibody specificity is critical for generating reliable research data. To rigorously evaluate YEATS2 antibody specificity:

• Knockout/knockdown validation: Implement CRISPR-Cas9 knockout or siRNA knockdown of YEATS2 in your experimental system and confirm loss of signal.

• Peptide competition assays: Pre-incubate the antibody with excess immunizing peptide before application to samples—specific signals should be blocked.

• Western blot assessment: Confirm detection of a single band at the expected molecular weight (151 kDa for YEATS2) .

• Cross-species reactivity testing: If working with non-human models, validate reactivity with the species-specific YEATS2 protein, as the antibody has been primarily tested against human YEATS2 with predicted reactivity in other species .

• Multiple antibody comparison: When possible, compare results using antibodies targeting different epitopes of YEATS2 to confirm consistency of findings.

What approaches can be used to study the dynamic interaction between YEATS2 and histone modifications?

To investigate YEATS2's role as a histone crotonylation reader and its involvement in histone acetylation, researchers can employ these methodological approaches:

• Chromatin Immunoprecipitation (ChIP): Use YEATS2 antibodies to precipitate chromatin fragments, followed by sequencing (ChIP-seq) or qPCR to identify genomic binding sites. This can be coupled with histone modification ChIP to correlate YEATS2 binding with specific histone marks.

• Proximity Ligation Assay (PLA): Visualize protein-protein interactions between YEATS2 and modified histones in situ at the single-cell level.

• Co-Immunoprecipitation: Use YEATS2 antibodies to precipitate protein complexes (using conditions validated in Jurkat cells) , followed by Western blotting for associated histone proteins or other ATAC complex components.

• FRET/BRET approaches: Employ fluorescence or bioluminescence resonance energy transfer to study real-time dynamics of YEATS2 interactions with modified histones in living cells.

• Recombinant protein interaction studies: Express and purify YEATS2 domains to perform in vitro binding assays with modified histone peptides, quantifying interactions through biophysical methods like isothermal titration calorimetry or bio-layer interferometry.

How can I address non-specific background when using YEATS2 antibodies in immunohistochemistry?

High background in IHC applications using YEATS2 antibodies can compromise data interpretation. To methodically reduce background:

• Optimize antibody dilution: Test a range of dilutions beyond the recommended 1:20-1:200 range to identify the optimal signal-to-noise ratio for your specific tissue type .

• Refine antigen retrieval: Compare TE buffer (pH 9.0) and citrate buffer (pH 6.0) performance in your specific samples, as retrieval conditions significantly impact YEATS2 epitope accessibility .

• Block endogenous peroxidase and biotin: Implement hydrogen peroxide treatment before antibody incubation and use avidin-biotin blocking if using biotin-based detection systems.

• Adjust blocking conditions: Extend blocking time (1-2 hours) and test different blocking reagents (BSA, normal serum, commercial blockers) to identify optimal formulation for your tissue.

• Modify washing protocols: Increase wash duration and volume to ensure complete removal of unbound antibody, particularly in tissues with high endogenous binding sites.

• Include additional controls: Process sections with isotype-matched control antibodies to distinguish non-specific binding from true YEATS2 signal.

What are potential causes and solutions for inconsistent YEATS2 detection in Western blotting?

Inconsistent results when detecting YEATS2 via Western blotting may stem from several factors. A systematic troubleshooting approach includes:

• Sample preparation optimization:

  • Ensure complete protein denaturation by heating samples at 95°C for 5 minutes in loading buffer

  • Use protease inhibitors in lysis buffer to prevent YEATS2 degradation

  • Optimize lysis conditions to ensure complete extraction of nuclear proteins

• Transfer efficiency assessment:

  • For the large 151 kDa YEATS2 protein, use low-percentage gels (6-8%) and extend transfer time

  • Consider semi-dry versus wet transfer methods to optimize large protein transfer

  • Validate transfer using reversible total protein stains

• Antibody incubation conditions:

  • Optimize antibody concentration within the 1:200-1:1000 recommended range

  • Test both overnight 4°C and room temperature incubations

  • Consider addition of 0.05% Tween-20 to reduce non-specific binding

• Detection system sensitivity:

  • For low abundance YEATS2, switch to more sensitive detection systems

  • Compare HRP-conjugated versus fluorescence-based secondary antibodies

  • Adjust exposure times to optimize signal detection

• Positive control inclusion:

  • Always run Jurkat cell lysate as a positive control for YEATS2 detection

  • Consider including recombinant YEATS2 protein as a reference standard

How can AI-based antibody design approaches be applied to develop improved YEATS2-targeting antibodies?

Recent advances in AI-based antibody design offer opportunities to develop enhanced YEATS2 antibodies with improved specificity and affinity. Methodological implementation includes:

• Computational epitope mapping: Use AI algorithms to identify optimal YEATS2 epitopes with high antigenicity and minimal similarity to other proteins, increasing specificity.

• Structure-guided design: Apply AlphaFold-Multimer (2.3/3.0) to accurately model YEATS2-antibody complexes without requiring templates, enabling rational design of binding interfaces .

• Affinity optimization: Implement FlexddG computational methods to predict single point mutations that could enhance binding affinity to YEATS2 epitopes without compromising specificity .

• Developability assessment: Apply "Naturalness" metrics to designed antibodies to predict desirable developability profiles and low immunogenicity potential .

• Zero-shot design validation: Generate multiple antibody candidates through generative deep learning models and validate through high-throughput screening approaches, as demonstrated for other target proteins .

The IsAb2.0 protocol represents a promising approach for future YEATS2 antibody development, requiring only input sequences of antibody and antigen to generate optimized binding candidates .

What methodologies can assess the immunogenicity risk of engineered YEATS2 antibodies?

For researchers developing modified YEATS2 antibodies, assessing immunogenicity risk is crucial. Methodological approaches include:

• In vitro PBMC-based assays: Implement peripheral blood mononuclear cell tests that measure IL-2-secreting CD4+ T cells induced by antibody candidates, providing results within 3 days that correlate with clinical immunogenicity risk .

• Humanness prediction models: Apply computational models trained on patent data using multi-stage, multi-loss training processes to predict the humanness score of YEATS2 antibody sequences, which serves as a proxy for immunogenic potential .

• Sequence-based risk assessment: Analyze engineered YEATS2 antibody sequences for potential T-cell epitopes and compare with human germline sequences to identify potentially immunogenic regions.

• Structural analysis: Evaluate surface exposure of modified residues and their potential to create novel epitopes that might trigger immune recognition.

• Comparative analysis: Benchmark candidate YEATS2 antibodies against antibodies with known immunogenicity profiles such as etanercept (1.9% response), emicizumab (3.8% response), or other reference antibodies .

The combination of computational prediction and in vitro validation provides a comprehensive approach to immunogenicity risk assessment before advancing engineered YEATS2 antibodies to in vivo testing.

How can high-throughput approaches be implemented for YEATS2 antibody validation across diverse experimental contexts?

To comprehensively validate YEATS2 antibodies across multiple applications and sample types, researchers can implement these high-throughput methodological approaches:

• Tissue microarray screening: Simultaneously assess YEATS2 antibody performance across dozens of normal and pathological tissue types to establish tissue-specific staining patterns and optimal IHC conditions.

• Cell line panel validation: Test antibody performance across a diverse panel of cell lines with varying YEATS2 expression levels to establish detection limits and confirm specificity across cellular contexts.

• Multi-omics correlation: Correlate antibody-based YEATS2 protein detection with RNA-seq data for YEATS2 mRNA expression to validate detection accuracy and identify potential discrepancies between transcription and protein levels.

• Automated image analysis: Implement machine learning-based image analysis for IHC results to quantitatively assess YEATS2 staining patterns across large sample sets with reduced subjective interpretation.

• Cross-platform validation: Systematically compare YEATS2 detection across multiple platforms (flow cytometry, ELISA, Western blot, IHC) using standardized samples to establish platform-specific performance characteristics.

These approaches enable robust validation while generating comprehensive datasets on YEATS2 expression patterns across diverse biological contexts.